CDC42 and ovarian carcinoma: ML141 has been demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 activation in MDA-MB-231 cells [49], human ovarian carcinoma cell lines (OVCA429 and SKOV3ip) [48], and pancreatic cancer cell lines (BxPC-3, Panc-1 and HPAF II) [13].